N-(1-甲基乙基)-3-哌啶胺 | 1235439-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-(1-甲基乙基)-3-哌啶胺
• 英文名称: N-(propan-2-yl)piperidin-3-amine
• 英文别名: N-propan-2-ylpiperidin-3-amine
• CAS: 1235439-19-6
• 化学式: C₈H₁₈N₂
• 分子量: 142.24
• InChiKey: XAXUUHPCEVNZFT-UHFFFAOYSA-N

物化性质

• 沸点：
  194℃
• 密度：
  0.89
• 闪点：
  68℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
  申请人：Samumed, LLC

  公开号：US20190125740A1

  公开（公告）日：2019-05-02

  Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

  揭示了用于治疗各种疾病和病理的异喹啉化合物。更具体地，本公开涉及使用异喹啉化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、炎症、自身免疫疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及与DYRK1A过表达相关的神经状况/疾病/疾病。
• PYRROLOPYRAZINE INHIBITORS OF KINASES
  申请人：Penning Thomas D.

  公开号：US20110015172A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及式(I)的化合物或药用可接受的盐，其中R1a、R1b、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制Cdc7等激酶并治疗癌症等疾病的方法。
• ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
  申请人：Samumed, LLC

  公开号：US20170313682A1

  公开（公告）日：2017-11-02

  Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  揭示了用于治疗各种疾病和病理的异喹啉化合物。更具体地，本发明涉及使用异喹啉化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理条件/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• [EN] NLRP3 MODULATORS<br/>[FR] MODULATEURS DE NLRP3
  申请人：INNATE TUMOR IMMUNITY INC

  公开号：WO2019014402A1

  公开（公告）日：2019-01-17

  The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

  本发明提供了Formula (I)的化合物：(I)其中所有变量均如本文所定义。这些化合物是NLRP3的调节剂，可用作治疗增殖性疾病的药物，例如在受试者（例如人类）中的癌症治疗。
• UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF
  申请人：RAPT THERAPEUTICS, INC.

  公开号：US20210317134A1

  公开（公告）日：2021-10-14

  Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.

  本公开的内容包括化合物及其使用方法，用于调节USP7活性。